Finding the biomarkers of response to anti-VEGF treatment is today a priority of the research, according to Marc De Smet, MD, PhD. Response is widely variable, and biomarkers will help tailoring treatment options to the needs of individual patients.
Perspective: Marc De Smet, MD, PhD
Other Perspective
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
Defining Nonadherence and Nonpersistence to Anti-VEGF Therapies in nAMD
The nAMD Barometer Leadership Coalition published a definition for nonadherence and nonpersistence
Related Articles
